Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John A Hickman

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Current Opinion in Genetics & Development|January 16, 2002
Apoptosis and tumourigenesisJohn A Hickman
Current Opinion in Pharmacology|July 20, 2002
Changes and challenges--the world post-Gleevec (Glivec)John A Hickman, John S Lazo
The New England Journal of Medicine|January 5, 2017
Limits to Precision Cancer MedicineIan F Tannock, John A Hickman
The New England Journal of Medicine|September 30, 2016
Limits to Personalized Cancer MedicineIan F Tannock, John A Hickman
The Lancet. Oncology|June 6, 2020
Knowing your tumour?Ian F Tannock, John A Hickman
BMJ Oncology|February 19, 2026
Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitorsEmily S Zhang, Leeza Osipenko, John A Hickman
Biochimica Et Biophysica Acta|March 5, 2004
Shooting at survivors: Bcl-2 family members as drug targets for cancerPhilippe Juin, Olivier Geneste, Eric Raimbaud, et al.
JAMA Network Open|July 28, 2023
Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor InhibitorsValerie Jentzsch, Leeza Osipenko, Jack W Scannell, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2021
The European Union and personalised cancer medicineJohn A Hickman, Ian F Tannock, Lydie Meheus, et al.
The Journal of Biological Chemistry|November 25, 2004
Exposure to hypoxia rapidly induces mitochondrial channel activity within a living synapseElizabeth A Jonas, John A Hickman, J Marie Hardwick, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Current Opinion in Genetics & Development|January 16, 2002
Apoptosis and tumourigenesisJohn A Hickman
Current Opinion in Pharmacology|July 20, 2002
Changes and challenges--the world post-Gleevec (Glivec)John A Hickman, John S Lazo
The New England Journal of Medicine|January 5, 2017
Limits to Precision Cancer MedicineIan F Tannock, John A Hickman
The New England Journal of Medicine|September 30, 2016
Limits to Personalized Cancer MedicineIan F Tannock, John A Hickman
The Lancet. Oncology|June 6, 2020
Knowing your tumour?Ian F Tannock, John A Hickman
BMJ Oncology|February 19, 2026
Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitorsEmily S Zhang, Leeza Osipenko, John A Hickman
Biochimica Et Biophysica Acta|March 5, 2004
Shooting at survivors: Bcl-2 family members as drug targets for cancerPhilippe Juin, Olivier Geneste, Eric Raimbaud, et al.
JAMA Network Open|July 28, 2023
Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor InhibitorsValerie Jentzsch, Leeza Osipenko, Jack W Scannell, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2021
The European Union and personalised cancer medicineJohn A Hickman, Ian F Tannock, Lydie Meheus, et al.
The Journal of Biological Chemistry|November 25, 2004
Exposure to hypoxia rapidly induces mitochondrial channel activity within a living synapseElizabeth A Jonas, John A Hickman, J Marie Hardwick, et al.
Pageof 5